AAS
AMPH icon

Annex Advisory Services’s Amphastar Pharmaceuticals AMPH Stock Holding History

Annex Advisory Services’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,777
Closed -$649K – 284
2024
Q1 		$649K Buy
14,777
+917
+7% +$47.4K 0.02% 159
2023
Q4 		$857K Buy
13,860
+9,435
+213% +$496K 0.04% 134
2023
Q3 		$204K Buy
+4,425
New +$241K 0.01% 244

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annex Advisory Services's AMPH Position: Q2 2024 in Review

Annex Advisory Services sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2024, closing a stake of 14,777 shares — an estimated $649K sold.

Annex Advisory Services first reported a position in AMPH in Q3 2023 and held it in 3 quarters. The position peaked at $857K in Q4 2023. 269 funds tracked by Wall St. Rank hold AMPH as of Q2 2024.

  • Annex Advisory Services reported no remaining Amphastar Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Annex Advisory Services sold 14,777 Amphastar Pharmaceuticals shares in Q2 2024, an estimated $649K.
  • Annex Advisory Services first reported a position in Amphastar Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Annex Advisory Services's Amphastar Pharmaceuticals position peaked at $857K in Q4 2023.
  • 269 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2024.

Based on Annex Advisory Services's 13F filing for Q2 2024, filed 12 Jul 2024.